智通财经网·2025-05-15 12:26Group 1: Company Announcements - Heng Rui Pharmaceutical has completed its share repurchase plan, spending approximately 600 million yuan, repurchasing 12.9051 million shares, which is 0.20% of the total share capital, with an average repurchase price of about 46.59 yuan per share [1] - Chengdi Xiangjiang's wholly-owned subsidiary signed an EPC general contracting contract with China Mobile for a project worth 1.632 billion yuan, which is expected to positively impact future revenue [2] - Jingyuan Environmental Protection's wholly-owned subsidiary signed a contract for a computing cluster construction project worth 365 million yuan, with a gross profit margin of approximately 9% to 10% [3] Group 2: Legal and Regulatory Issues - China Chemical's subsidiary is involved in a lawsuit concerning false statements related to securities, with a claim for damages amounting to 5.147 billion yuan [4] - ST Huijin has applied to revoke its other risk warning status after addressing issues from a previous administrative penalty, pending approval from the Shenzhen Stock Exchange [5] Group 3: Stock Performance and Risks - Ningbo Shipping's stock has seen a significant short-term increase, with a cumulative price deviation exceeding 20% over three trading days, indicating potential trading risks [6] - Lianyungang's stock has also experienced a similar short-term price increase, with a 48.01% year-on-year decline in net profit for the first quarter [7] - Xinhua Jin has reported potential risks of administrative penalties or disciplinary actions from the China Securities Regulatory Commission due to uncertainties in export business [8]